Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fucoran
- Development stage
- Preclinical
- Lead developer
- CellMed
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Fucoran is a natural product candidate developed by CellMed, formulated as a fucoidan polysaccharide extract. It is positioned within CellMed's natural drug pipeline for the improvement of immune function. Fucoidans are complex sulfated polysaccharides derived primarily from various species of brown seaweed (Phaeophyceae), known for their diverse biological activities, including immunomodulatory, antioxidant, and anti-inflammatory effects. Fucoran is intended to enhance the body's immune response, potentially by modulating the activity of immune cells such as natural killer (NK) cells and macrophages. While it is being developed through clinical phases, its specific molecular targets and detailed mechanism of action have not been publicly disclosed by the developer.
- Brand names
- Fucoran
- Other names
- fucoidan polysaccharide extract
02
Targets
MSR1 (Amyloid beta precursor protein binding family B member 3)TLR4 (Toll-like receptor 4)αMβ2 (Integrin αMβ2)ERC (Elastin receptor complex)TLR2 (Toll-like Receptor 2)MRC1 (Mannose Receptor C-type 1)
Beyond the preview
Go deeper on Fucoran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fucoran.